Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sleep apnea & airway implants cases in Oklahoma: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (12 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2022 | 2 | 79 | 38% |
| 2023 | 4 | 96 | 42% |
| 2024 | 4 | 126 | 44% |
Hypoglossal nerve stimulation and upper airway procedures. Professional codes (what the surgeon bills): CPT 64582, 64583, 64584, 42145, 41530.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oklahoma; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 17 | 2,185+7.6%/yr | +7.6%/yr | 4.50.9× | 69% | 3,570 in 2030+8.5%/yr |
| Ear tubes & middle ear surgery |
Sleep apnea & airway implants in every state, and its device makers · Every procedure market in Oklahoma · Every state · Compare with Texas
| 2025 from claims |
| – |
| 118 95–139 |
| 46% |
| 2026 forecast | – | 128 100–161 | 46% |
| 2027 forecast | – | 139 103–184 | 47% |
| 2028 forecast | – | 151 107–209 | 48% |
| 2029 forecast | – | 164 111–235 | 49% |
| 2030 forecast | – | 178 117–264 | 49% |
In 2025, 100% hospital outpatient.
| +55%/yr |
| 0.2 |
| 6% |
| 600 in 2030+3.1%/yr |
| Georgia | 8 | 238+64%/yr | +64%/yr | 0.3 | 6% | 380 in 2030+8.2%/yr |
| South Carolina | 8 | 218+73%/yr | +73%/yr | 0.3 | 0% | 400 in 2030+10%/yr |
| Mississippi | 4 | 204+118%/yr | +118%/yr | 0.5 | 0% | 280 in 2030+5.3%/yr |
| North Carolina | 6 | 178+96%/yr | +96%/yr | 0.2 | 0% | 270 in 2030+7%/yr |
| Alabama | 3 | 154+128%/yr | +128%/yr | 0.3 | 0% | 140 in 2030−1.5%/yr |
| Louisiana | 5 | 148+58%/yr | +58%/yr | 0.3 | 0% | 150 in 2030−0.3%/yr |
| Virginia | 4 | 141+51%/yr | +51%/yr | 0.1 | 11% | 190 in 2030+5.4%/yr |
| Tennessee | 4 | 136+52%/yr | +52%/yr | 0.2 | 0% | 200 in 2030+6.7%/yr |
| Kentucky | 3 | 122+0.3%/yr | +0.3%/yr | 0.3 | 0% | 70 in 2030−7.9%/yr |
| 4 |
| 232−2.9%/yr |
| −2.9%/yr |
| 0.51.5× |
| 12% |
| 150 in 2030−6.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Inspire Medical Systems leads with 92% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 6 companies reported engagement with Oklahoma’s surgeons worth $42K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 18 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.